Nitric oxide (NO) regulates a number of essential physiological processes by activating soluble guanylate cyclase (sGC) to produce the second messenger cGMP. The mechanism of NO sensing was previously thought to result exclusively from NO binding to the sGC heme; however, recent studies indicate that heme-bound NO only partially activates sGC and additional NO is involved in the mechanism of maximal NO activation. Furthermore, thiol oxidation of sGC cysteines results in the loss of enzyme activity. Herein the role of cysteines in NO-stimulated sGC activity investigated. We find that the thiol modifying reagent methyl methanethiosulfonate specifically inhibits NO activation of sGC by blocking a non-heme site, which defines a role for sGC cysteine(s) in mediating NO binding. The nature of the NO/cysteine interaction was probed by examining the effects of redox active reagents on NO-stimulated activity. These results show that NO binding to, and dissociation from, the critical cysteine(s) does not involve a change in the thiol redox state. Evidence is provided for non-heme NO in the physiological activation of sGC in context of a primary cell culture of human umbilical vein endothelial cells. These findings have relevance to diseases involving the NO/cGMP signaling pathway.
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thiol ͉ TC-1 ͉ cGMP ͉ S-nitrosation ͉ redox C ardiovascular disease is the leading cause of death in the United States and the enzyme soluble guanylate cyclase (sGC) is a therapeutic target for treatment of the disease. sGC is the central protein in the nitric oxide (NO)/cGMP signaling cascade, a pathway that mediates diverse physiological functions including vasodilation, platelet aggregation, and neurotransmission (1) (2) (3) . Although Ͼ20 years have passed since sGC was identified as the primary eukaryotic NO receptor (4), our understanding of the molecular details of sGC activation by NO continues to evolve.
sGC is a heterodimeric hemoprotein consisting of an 80-kDa ␣ subunit and a 70-kDa ␤ subunit. In mammals, there are two isoforms for each subunit, and the N-terminal domain (Ϸ200 residues) of the ␤ subunit binds a heme cofactor. The unliganded enzyme exhibits a low level of cGMP production and is referred to as the basal state. NO coordination to the sGC heme has been thoroughly investigated and was presumed to cause the conversion of the unactivated basal enzyme to the activated NO-bound enzyme. Indeed, coordination of NO to the sGC heme cofactor correlates with a large increase of sGC activity (5, 6); however, we and others have recently demonstrated that NO ligation to the heme is not sufficient to fully activate sGC (7, 8) .
NO initially binds to the sGC heme with picomolar affinity (9, 10), inducing a moderate activation of the enzyme (7, 8) . This low activity form of the enzyme maintains a 1:1 stoichiometry of NO to sGC, and we refer to it henceforth as the 1-NO state. This 1-NO state exhibits a slow rate of NO dissociation (11, 12) and, as a consequence, this form of the enzyme can be stably isolated away from free NO in solution (7, 8, 13) . The subsequent addition of excess NO to the 1-NO state further stimulates sGC to a high activity form that we refer to as the xsNO state. The xsNO state is spectrally identical to the 1-NO state, but it only persists in the presence of excess NO. When NO is removed from solution, the high activity of the xsNO state rapidly reverts to the low activity of the 1-NO state. Thus, all three sGC states (basal, 1-NO, and xsNO) can be prepared and studied in vitro (7, 8) . Importantly, these results define two different states of purified sGC with heme bound NO (7, 8) , one with a high activity and one with a low activity.
Further evidence for a non-heme NO binding site was obtained by blocking the heme site with the tight-binding ligand butyl isocyanide, and then showing that NO still activated the enzyme (14) . The dependence of sGC function on the non-heme NO binding site draws specific attention to its nature. There is precedent for reversible gaseous ligand binding in proteins involving a nonheme metal (15) or a hydrophobic binding pocket (16) ; however, sGC is isolated with only the heme iron, and other hydrophobic diatomic gasses such as N 2 , CO, and O 2 fail to stimulate the enzyme. A plausible mechanism that could account for the selectivity of NO is through a transient reaction with a cysteine thiol.
In this work, we investigate the function of cysteines in the mechanism of non-heme NO activation and demonstrate a physiological role for non-heme NO activation. Our results suggest that oxidative damage can block the non-heme NO binding site, consequently inhibiting NO stimulation of sGC in vivo. Importantly, these results provide a mechanistic explanation for observations of sGC inhibition by thiol modifying reagents and oxidants (17) (18) (19) , and it is therefore relevant toward addressing the molecular mechanism of NO tolerance (19, 20) , a disease state characterized by a decreased sensitivity to NO in cardiovascular tissue. Additionally, each sGC state (basal, 1-NO, and xsNO) may be a unique target for therapeutic intervention in diseases involving sGC dysfunction.
non-essential activator for the binding to both the heme and non-heme sites. Therefore, each NO binding event induces a distinct conformational change in the active site.
Non-Heme NO Activation Is Mediated by Cysteine(s). To examine the involvement of sGC cysteines in the mechanism of NO activation, the effect of a thiol reactive reagent on enzyme activity was tested. In these experiments rat ␣1␤1 sGC was recombinantly expressed in a Sf9/baculovirus system and purified to homogeneity. Purified protein was then treated with the thiol reactive probe methyl methanethiosulfonate (MMTS), which modifies thiols through the formation of methyl disulfides (Eq. 1).
Because this reaction yields a disulfide product, it is reversible with thiol reductants like DTT. We found that MMTS inhibited NO stimulated sGC activity (Fig. 1A) , but electronic absorption spectroscopy showed that MMTS did not prevent the formation of the ferrous-nitrosyl complex (Fig. S1 ). This MMTS-treated ferrous-nitrosyl complex was not stimulated by treatment with additional NO, but the allosteric activator YC-1 was able to activate the protein. YC-1 is an indazole derivative that weakly activates the basal enzyme, but strongly stimulates sGC activity when a ligand is coordinated to the heme (14, 21, 22) . The observation of a MMTS-treated ferrous-nitrosyl complex demonstrates that thiol modification does not interfere with NO binding to the heme. Additionally, MMTS (Ն100 M) did not inhibit basal sGC activity (Fig. 1B) , which shows that the protein did not denature with MMTS treatment and that essential catalytic residues were not modified. MMTS inhibition of sGC was fully reversible by DTT (Fig. 1C) , demonstrating that the protein structure is not irreversibly damaged by the reaction. These results show that MMTS specifically inhibits the activation of sGC that results from NO binding.
Interestingly, NO stimulation of MMTS-treated sGC resulted in activity that is similar to that of the low-activity 1-NO form of the enzyme (Fig. 1D) . The observation that MMTS specifically inhibits NO stimulation led us to investigate whether cysteine modification by MMTS inhibits non-heme NO binding. To address this question, MMTS was titrated against sGC and NO stimulated activity was measured (Fig. 1E ). NO stimulated activity is inhibited at low M MMTS and is zero order in MMTS between 15 and 100 M. At concentrations Ͼ100 M, an irreversible loss in both basal and NO stimulated activity was observed. Therefore, high concentrations of MMTS lead to a general, nonspecific inhibition of sGC (17) . However, the observation of a saturated range of MMTS inhibition implicates a discrete set of cysteines in the mechanism of non-heme NO activation. This saturating effect of MMTS leaves the enzyme synthesizing cGMP at a rate that matches that of the 1-NO species. If modification caused a nonspecific disruption of catalysis, the protein would be completely inhibited at saturating concentrations of MMTS. Also, because MMTStreated sGC was stimulated by the combination of both NO and YC-1 (Fig. 1A) , MMTS does not sterically hinder the transition to the high activity state. Therefore, our observation that MMTS-treated sGC maintains partial NO stimulation, combined with the observation that MMTS-treated sGC binds NO at the heme, suggests that the transition from the 1-NO state to the xsNO state is impaired by cysteine modification. Thus, MMTS blocks the cysteine(s) that constitute the non-heme NO binding site.
To assess the role of cysteines in regulating NO activation in vivo, MMTS inhibition of sGC activity in PC12 cells, a rat tumor cell line that endogenously expresses sGC (23) was examined (Fig. 1F ). Similar to purified protein, the NO stimulated sGC activity exhibited a zero order dependence on MMTS between 100 and 300 M. This indicates that reduced cysteines are necessary for activation beyond the 1-NO level of stimulation in vivo. The range of zero order activity in PC12 cells differs from purified protein, likely owing to endogenous intracellular reductants. Additionally, because thiol modification with MMTS inhibits NO stimulated activity in vivo, it is possible that other reactants (more specifically intracellular oxidants) may inhibit cGMP production by reaction with the same cysteine. In fact, we have observed sGC inhibition in vitro with molecular oxygen as well as the thiol alkylating reagent N-ethyl maleimide (NEM) (Fig. S2 ). Because both reactive oxygen species and decreased sGC activity are associated with cardiovascular disease (24) , it is an attractive hypothesis that cysteine oxidation of the non-heme NO binding site causes symptoms in some forms of the Rates acquired at 25°C.
[1] disease. This cysteine oxidation would not affect cGMP production in either the basal or 1-NO sGC states but would significantly impair that derived from the xsNO state. These results provide a causative molecular mechanism to observations that cysteine oxidation correlates with reduced sGC activity (17) (18) (19) .
Characterization of sGC Cysteines Labeled by MMTS.
Because the reaction of MMTS with sGC restricts activation beyond the 1-NO state, we sought to estimate the stoichiometry of this reaction. By labeling sGC cysteines with MMTS and then exchanging the methyl disulfide modification for a biotin tag, the extent of the MMTS reaction can be readily visualized ( Fig. 2A) and quantified (Fig. 2B) . The MMTS reaction with sGC saturates (␣1 EC 95 ϭ 34 Ϯ 7 M; ␤1 EC 95 ϭ 36 Ϯ 5 M) and the labeling intensity can be used to estimate the number of MMTS-reactive cysteines by standardizing the labeling intensity to that of denatured sGC reacted with excess MMTS, where all cysteine residues are expected to react (20 cysteines in ␣1 and 14 in ␤1) (Fig. S3 ). This analysis projects that 16 Ϯ 3 cysteines on ␣1 and 10 Ϯ 1 cysteines on ␤1 react with MMTS under native conditions. Furthermore, at the minimally sufficient MMTS concentration to fully inhibit sGC (IC 95 ϭ 16 Ϯ 2 M, dotted vertical line Fig. 2B ), MMTS has reacted with 12 Ϯ 2 cysteines on ␣1 and 8 Ϯ 1 cysteines on ␤1. Saturation of NO stimulated activity occurs at a lower concentration than the saturation of labeling, suggesting that the cysteine(s) of the non-heme NO binding site is more reactive to MMTS. To map the cysteines that are reactive to MMTS, the MMTS-treated sGC was proteolyzed with trypsin. Analysis of the digests by mass spectrometry identified several MMTS-reactive residues ( Table 2 ). The key residue(s) comprising the non-heme NO binding site is likely contained within the set of MMTS-modified cysteines.
The NO/Cysteine Interaction Is Reversible in the Absence and Presence of Redox Active Reagents. In the cellular milieu, there is an abundance of both oxidants and reductants, and, as a consequence, instances of cysteine oxidation are frequently reversed by endogenous reductants. Likewise, commonly used assay buffers for in vitro experiments also contain oxidants in the form of O 2 and reductants in the form of DTT. To test the redox chemistry of the NO/cysteine interaction in sGC, the effect of these redox active reagents on NO-mediated cysteine oxidation and enzyme activation was examined. Nitrosothiols are gaining recognition as biologically relevant posttranslational modifications (25) . We sought to determine whether S-nitrosation could be responsible for NO induced sGC activation. As mentioned above, S-nitrosation is an oxidative addition of NO to a thiol that requires a redox partner to act as an electron sink, and most often oxygen serves this role in vitro (Eq. 2):
Indeed, the aerobic addition of NO to sGC produces nitrosothiols (Fig. 3A) (19) while concurrently stimulating the enzyme several hundred fold (Fig. 3B) . If the activating species were a nitrosothiol, then conditions that prevent S-nitrosation must also prevent NO stimulation. However, under anaerobic conditions and in the absence of reductant, NO-stimulated sGC was neither S-nitrosated nor inhibited (Fig. 3 A and B) . Furthermore, because NO activated sGC to the same extent with and without O 2 , the mechanism of 
. [2]
enzyme activation is likely the same under anaerobic and aerobic conditions. Thus, the observation of maximal NO stimulation of sGC without S-nitrosation excludes a nitrosothiol as the cysteine modification involved in sGC activation by NO. The observation of maximal NO stimulation with Snitrosation under aerobic conditions presents an apparent discrepancy with literature reports that S-nitrosation of specific sGC cysteines (␤1C122 and ␣1C243) inhibits sGC activity (19) . This discrepancy can be reconciled by noting the difference in assay conditions between the work reported here and the previously published report. The experiments presented here were designed to study the molecular events of NO stimulation of sGC and, accordingly, a short reaction with the NO donor DEA/NO was used. However, the experiments that identified an inhibitory action of S-nitrosation were designed to simulate conditions of physiological NO tolerance; therefore a relatively long reaction with S-nitrosoglutathione (GSNO) was used (19) . Furthermore, GSNO acts primarily through transnitrosation whereas the mechanism of S-nitrosation by NO typically proceeds through the reaction with O 2 . Because of the difference in nitrosating reagents and reaction conditions, different cysteine residues will react to different extents in each experiment. Therefore, although our data eliminates a role for a nitrosothiol in the activation of sGC, it does not conflict with the proposal that S-nitrosation is involved in the mechanism of NO tolerance (19, 26, 27) .
To further explore the role of redox chemistry in the NO/ cysteine interaction, the reversibility of sGC activity in the absence of commonly used redox reactive reagents, such as O 2 and DTT was studied. As discussed above, sGC can be fully activated by NO in the absence of O 2 and DTT (Fig. 3B) . If NO activation was caused by an NO-induced oxidation, NO stimulation would not be reversible without a reductant. To assess the reversibility of this reaction anaerobically, the xsNO species was formed and then excess NO was removed from solution to form the low-activity 1-NO species (Fig. 3C) . The activity of both the xsNO and 1-NO species with or without O 2 and DTT is similar (Figs. 1D and 3C ). The 1-NO sGC species was then restimulated with NO, and the enzyme regained full activation (1-NO ϩ NO in Fig. 3C ). Thus, just as activation by NO did not require an oxidation of sGC, deactivation and restimulation did not require a reduction of sGC. Because sGC activation is rapidly reversible in the absence of redox mediators, we conclude that the activating species does not alter the oxidation state of the key cysteine(s). Furthermore, because the level of activity of each sGC state is unaffected by anaerobic conditions, we propose that the mechanism of activation and deactivation is O 2 -independent. Additionally, the necessity for a reduced thiol in the non-heme NO binding site provides a specific mechanism for the inhibition of NO stimulated activity by thiol oxidation (17, 18, 20) and S-nitrosation (19, 26) . A chemical species that could account for these observations is the direct nucleophilic addition of a thiol to NO, which yields RSNO ⅐Ϫ . This species differs from a nitrosothiol by only one electron, but this small difference imparts radically different properties. As opposed to the relative stability of nitrosothiols, this species has been proposed as a short-lived intermediate in reactions that yield disulfides, sulfenic acids, and nitrosothiols (28) (29) (30) and has been characterized as a reversible adduct on hemoglobin (31) . The characteristic of rapid reversibility is consistent with the rapid deactivation of sGC from the xsNO state to the 1-NO state.
Investigation of cGMP Regulation by NO in HUVECs.
Decades of in vitro experiments have established that sGC activation requires the coordination of NO to the heme; however, a NO-bound species has not been directly observed in vivo. Spectroscopy is the standard method of detection for the ligation state of a hemoprotein (32) , but the complexity of cellular constituents and the low abundance of sGC in vivo severely limit the utility of spectroscopy in cells. Therefore, to observe the sGC heme coordination state in vivo, we have used an alternative assay that capitalizes on the small molecule sGC activator YC-1 (22) . YC-1 activates sGC to different degrees depending on the heme ligation state (21, 33) . Although the precise mechanism of YC-1 activation is still under investigation, YC-1 can be used to distinguish sGC heme ligation states by the differential activation of the 1-NO state compared with the basal state or the xsNO state (Fig. 4A) (7) .
To assess the heme ligation state of sGC in vivo, cGMP formation in human umbilical vein endothelial cells (HUVECs) was examined. These cells constitutively express both sGC and NO synthase (NOS) and exhibit a low level of basal cGMP. Upon YC-1 treatment of HUVECs, a large increase in cGMP formation was observed. This YC-1-dependent increase in cGMP levels was prevented by a 2-h preincubation with N -nitro-Larginine methyl ester (L-NAME), a cell permeable NOS inhibitor (Fig. 4B ). This demonstrates a requirement for NO in the YC-1 mediated activation of sGC in vivo and others have observed similar phenomena in porcine aortic endothelial cells (PAECs) (34) , implicating a generality of this property in endothelial cells. Both the high fold activation of cGMP production induced by YC-1 and the inhibition of this activation by an extended pretreatment with L-NAME are consistent with the 1-NO state, however, the uncertainty of the local concentration of NO complicates this interpretation.
The kinetics of NO stimulation in vivo have been studied extensively (35, 36) . In response to NO, cells expressing sGC exhibit a rapid elevation in intracellular cGMP levels, followed by a fast decline in the rate of cGMP synthesis. This rapid deactivation has been previously assumed to reflect the simple dissociation of NO from the sGC heme. This would limit sGC to two defined states: an active NO-bound state and a basal NO-free state. However, experiments with purified protein suggest that the high activity, xsNO state may deactivate to the 1-NO state rather than the basal state (7). This possibility was tested in a cellular context with a time course assay in L-NAMEtreated HUVECs that were exposed to a burst of NO (delivered by PROLI/NO) in the presence of a phosphodiesterase (PDE) inhibitor (3-isobutyl-1-methylxanthine, IBMX). The sGC activity was then measured in both the early phase of NO stimulation (0-4 min) (Fig. 4C ) and the late phase of NO stimulation (5-10 min) (Fig. 4D) (Table 3 ). In the early phase, HUVECs displayed a well-documented accumulation of cGMP in response to NO, whereas untreated control HUVECs maintained a low, basal level of cGMP (Ϸ1 pmol/10 6 cells) (Fig. 4C ). This accounts for the two well-established states of sGC; the low activity of the basal state and the high activity of the xsNO state. In the late phase, the intracellular cGMP level reached a plateau indicative of the deactivated, low-activity sGC state (Fig. 4D) . In the late phase, both NO stimulated and untreated HUVECs exhibited low sGC activity which has been assumed to be the activity of basal sGC, i.e., no ligand bound to the heme. However, YC-1 treatment only stimulates sGC activity in the NO-treated cells, and the specific and prominent activation of only these cells discriminates between two long-lived, low-activity species with differing propensities toward YC-1 in vivo.
To simplify data analysis, the experiments described above were performed in the presence of a PDE inhibitor; however, in vivo PDEs are intimately linked to cGMP signaling and shape temporal changes in NO-induced intracellular cGMP levels (37) . Therefore, similar experiments were performed in the absence of IBMX, where we found that PDE activity did not affect the cellular responses under investigation (Fig. 4 E and F) . Importantly, under the conditions of this experiment, NO rapidly decays such that none was detected in solution after 4 min (Fig.  S4) , eliminating the uncertainty in local NO concentration.
These experiments suggest that sGC exists in three states in vivo: a low-activity state that is weakly stimulated by YC-1 (basal), a short-lived, high-activity state that is weakly stimulated by YC-1 (xsNO), and a longer-lived, low-activity state that is highly stimulated by YC-1 (Table 3) . Because this closely mirrors the activities of the spectroscopically defined states of sGC in vitro, this would appear to be a clear observation of the 1-NO state in vivo. With this evidence we propose a model of sGC activation where a reduced cysteine(s) stabilizes NO binding and produces a highly active sGC state (Fig. 5) . The rapid dissociation of the cysteine/NO complex deactivates the enzyme to the 1-NO state, which persists until NO slowly dissociates from the sGC heme and the enzyme reverts to the basal state.
Conclusion
In summary, our findings establish the importance of an sGC cysteine in the regulation of sGC by NO (Fig. 5) . Multiple NO binding sites impart a complexity of regulation to sGC which could be useful for the NO/cGMP signal transduction pathway because it intersects a great variety of physiological processes. It is noteworthy that both sites of NO interaction on sGC, a reduced thiol and a ferrous iron, are susceptible to oxidation. Therefore, in physiological instances of oxidative stress, it is possible that both cysteine oxidation and heme oxidation contribute to sGC dysfunction by preventing NO binding to each respective site. The interplay between these multiple sGC states and the molecular causes of dysfunction may offer an opportunity for the design of state-specific sGC activators to target diseased tissue (38, 39) .
Materials and Methods
sGC in Vitro Assays. Recombinant rat sGC was purified as described in ref. 14 and then DTT was removed from the sGC storage buffer using an anion exchange column. sGC was assayed in the presence and absence of MMTS (50 M), PROLI/NO (50 M) and YC-1 (150 M) where indicated, at room temperature. Assays were initiated with substrate, quenched after 3 min and cGMP was quantified. MMTS inhibition of sGC was directly compared with sGC activation by 1 equivalent of NO. sGC with NO only at the heme was formed by addition of substoichiometric amounts of PROLI/NO and spectrally monitoring the formation of the sGC-NO complex. Samples (sGC and sGC-NO) were then incubated with MMTS (30 M) and assays were initiated by addition of substrate at room temperature. Samples were quenched after 3 min and cGMP was quantified. Reversibility of MMTS inhibition was examined by adding DTT (5 mM) to MMTS-treated sGC, and quantifying cGMP production. To determine the inhibition profile of MMTS on NO-stimulated activity the concentration of MMTS was varied from 0 to 100 M. All assays were initiated by addition of MgCl 2 (3 mM) and GTP (1.5 mM) and cGMP was quantified. All HUVEC rates acquired at 37°C. For NO treatment, addition of 1 M PROLI/NO at t ϭ 0 min. Early phase is between 0 and 3 min and late phase is between 5 and 10 min. Velocity was determined by global analysis of mean measurements. ND, not determined. * , Velocity not statistically different from zero. Fig. 5 . Model for the role of cysteine(s) in the mechanism of sGC activation. NO initially binds to the heme and activates the enzyme Ϸ10-fold. In the presence of excess NO (xsNO), a putative thiol-NO adduct forms and this activates the enzyme Ϸ200-fold above the basal level. Although the exact chemical identity is unknown, a thionitroxide is proposed. This species is consistent with the observed properties of activation and deactivation. Under oxidative stress, the non-heme NO binding site oxidizes which prevents NO binding and, therefore, maximal activation. For simplicity, oxidation is only shown to affect the basal state, however, oxidation of the non-heme NO binding site in any state would desensitize sGC to NO.
